Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

JonDavid Sparks

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 19, 2023
APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trialsCynthia D Evans, JonDavid Sparks, Scott W Andersen, et al.
Journal of Biopharmaceutical Statistics|April 13, 2017
Statistical properties of continuous composite scales and implications for drug developmentHong Liu-Seifert, Scott Andersen, Michael Case, et al.
Drugs in Context|May 26, 2015
Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorderJames M Martinez, Margaret B Ferguson, Beth A Pangallo, et al.
The Journal of Clinical Psychiatry|April 2, 2016
Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatmentSusan G Ball, Margaret B Ferguson, James M Martinez, et al.
Neurology|February 20, 2025
ARIA Insights from the Donanemab Trials (P1-9.001)Steven Greenberg, Chakib Battioui, Ming Lu, et al.
The New England Journal of Medicine|March 15, 2021
Donanemab in Early Alzheimer's DiseaseMark A Mintun, Albert C Lo, Cynthia Duggan Evans, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 11, 2026
Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trialLars L Raket, Ming Lu, Cynthia D Evans, et al.
JAMA Neurology|March 10, 2025
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical TrialsJennifer A Zimmer, Paul Ardayfio, Hong Wang, et al.
JAMA|July 17, 2023
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical TrialJohn R Sims, Jennifer A Zimmer, Cynthia D Evans, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 19, 2023
APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trialsCynthia D Evans, JonDavid Sparks, Scott W Andersen, et al.
Journal of Biopharmaceutical Statistics|April 13, 2017
Statistical properties of continuous composite scales and implications for drug developmentHong Liu-Seifert, Scott Andersen, Michael Case, et al.
Drugs in Context|May 26, 2015
Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorderJames M Martinez, Margaret B Ferguson, Beth A Pangallo, et al.
The Journal of Clinical Psychiatry|April 2, 2016
Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatmentSusan G Ball, Margaret B Ferguson, James M Martinez, et al.
Neurology|February 20, 2025
ARIA Insights from the Donanemab Trials (P1-9.001)Steven Greenberg, Chakib Battioui, Ming Lu, et al.
The New England Journal of Medicine|March 15, 2021
Donanemab in Early Alzheimer's DiseaseMark A Mintun, Albert C Lo, Cynthia Duggan Evans, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 11, 2026
Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trialLars L Raket, Ming Lu, Cynthia D Evans, et al.
JAMA Neurology|March 10, 2025
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical TrialsJennifer A Zimmer, Paul Ardayfio, Hong Wang, et al.
JAMA|July 17, 2023
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical TrialJohn R Sims, Jennifer A Zimmer, Cynthia D Evans, et al.
Pageof 2